Literature DB >> 3610315

Effect of various diets on toxin production by two strains of Clostridium difficile in gnotobiotic mice.

S Mahe, G Corthier, F Dubos.   

Abstract

When axenic mice fed a commercial diet were monoassociated with two toxigenic strains of Clostridium difficile, 100% of them died 3 days after inoculation and both enterotoxin and cytotoxin were produced in their intestinal tract. However, when axenic mice were fed various semisynthetic diets before C. difficile challenge, some of them survived and their fecal cytotoxin and enterotoxin productions were highly reduced, whereas the C. difficile population level did not decrease to a great extent. Thus, gnotobiotic mice associated with C. difficile were a good model for the study of modulation by the dietary regimen of intestinal cytotoxin and enterotoxin production.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3610315      PMCID: PMC260604          DOI: 10.1128/iai.55.8.1801-1805.1987

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  [Microflora of the digestive system of the rat. I. Technics of study and proposed culture media].

Authors:  P Raibaud; A B Dickinson; E Sacquet; H Charlier; G Mocquot
Journal:  Ann Inst Pasteur (Paris)       Date:  1966-04

2.  Biological activities of toxins A and B of Clostridium difficile.

Authors:  D M Lyerly; D E Lockwood; S H Richardson; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

3.  Purification and characterization of toxins A and B of Clostridium difficile.

Authors:  N M Sullivan; S Pellett; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

4.  [Comparative study of the microbial flora of the stomach, small intestine and cecum in "holoxenic" (conventional) rats and its changes after various surgical interventions: blind jejunal loops or bile duct fistulae].

Authors:  E Sacquet; P Raibaud; J Garnier
Journal:  Ann Inst Pasteur (Paris)       Date:  1971-04

5.  Hydrolysis of urea in the gastrointestinal tract of "monoxenic" rats: effect of immunization with strains of ureolytic bacteria.

Authors:  M C Moreau; R Ducluzeau; P Raibaud
Journal:  Infect Immun       Date:  1976-01       Impact factor: 3.441

6.  Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc.

Authors:  H C Krivan; G F Clark; D F Smith; T D Wilkins
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

7.  Clostridium difficile in association with sporadic diarrhoea.

Authors:  R P Brettle; I R Poxton; J M Murdoch; R Brown; M D Byrne; J G Collee
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-23

8.  Immune response of the ileum to invasive Escherichia coli diarrheal disease in rabbits.

Authors:  P D O'Hanley; J R Cantey
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

9.  Clostridium difficile in gnotobiotic mice.

Authors:  A B Onderdonk; R L Cisneros; J G Bartlett
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

10.  Clostridium difficile and the aetiology of pseudomembranous colitis.

Authors:  H E Larson; A B Price; P Honour; S P Borriello
Journal:  Lancet       Date:  1978-05-20       Impact factor: 79.321

View more
  16 in total

1.  Effects of antibiotics and other drugs on toxin production in Clostridium difficile in vitro and in vivo.

Authors:  M C Barc; C Depitre; G Corthier; A Collignon; W J Su; P Bourlioux
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

2.  Fixation of Clostridium difficile toxin A and cholera toxin to intestinal brush border membranes from axenic and conventional mice.

Authors:  F Lucas; G W Elmer; E Brot-Laroche; G Corthier
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

3.  Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clostridium difficile infection in a cohort of hospitalized patients.

Authors:  L V McFarland; G W Elmer; W E Stamm; M E Mulligan
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

4.  Comparative nutritional and chemical phenome of Clostridium difficile isolates determined using phenotype microarrays.

Authors:  Joy Scaria; Jenn-Wei Chen; Nicodemus Useh; Hongxuan He; Sean P McDonough; Chunhong Mao; Bruno Sobral; Yung-Fu Chang
Journal:  Int J Infect Dis       Date:  2014-08-12       Impact factor: 3.623

5.  Evolution of the caecal epithelial barrier during Clostridium difficile infection in the mouse.

Authors:  M Heyman; G Corthier; F Lucas; J C Meslin; J F Desjeux
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

6.  Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates.

Authors:  Thomas Akerlund; Bo Svenungsson; Asa Lagergren; Lars G Burman
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

7.  Heterogeneity of Clostridium difficile isolates from infants.

Authors:  A Collignon; L Ticchi; C Depitre; J Gaudelus; M Delmée; G Corthier
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

8.  Emergence in gnotobiotic mice of nontoxinogenic clones of Clostridium difficile from a toxinogenic one.

Authors:  G Corthier; M C Muller
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

9.  Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A.

Authors:  G Corthier; M C Muller; T D Wilkins; D Lyerly; R L'Haridon
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

10.  Relationship between levels of Clostridium difficile toxin A and toxin B and cecal lesions in gnotobiotic mice.

Authors:  A Vernet; G Corthier; F Dubos-Ramaré; A L Parodi
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.